LXRX - Lexicon Pharmaceuticals Q3 top-line down 97% and bottom-line down 67%

Lexicon Pharmaceuticals (LXRX) Q3 results:Revenues: $6.63M (-97.7% Y/Y) vs consensus of $91.34M.XERMELO U.S. net sales were $6.5M.Net income: $82.6M (-66.7%); profit/share: $0.71 (-26.9%); Cash and Investments: $111.4M.Anticipated Near-Term Milestones: Q4 2020 – Initiation of a Phase 2 study for LX9211 in post-herpetic neuralgia. Presentation of data from the sotagliflozin SOLOIST and SCORED Phase 3 studies at the American Heart Association Scientific Sessions 2020.Q4 2021– Phase 2 study results in diabetic peripheral neuropathic pain and in post-herpetic neuralgia.Previously: Lexicon Pharmaceuticals EPS of $0.71 (Oct.29).Shares up 5.7% PM.

For further details see:

Lexicon Pharmaceuticals Q3 top-line down 97% and bottom-line down 67%